Treatment of whiplash by dopamine

Treatment of whiplash by pramipexole - a dopamine agonist

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2021-003574-31-DK

Enrollment

Registered

2021-07-09

Start date

2021-10-25

Completion date

Unknown

Last updated

2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

whiplash tension-type headache MedDRA version: 21.1 Level: LLT Classification code 10047930 Term: Whiplash injury to neck System Organ Class: 100000004863 MedDRA version: 21.1 Level: LLT Classification code 10043270 Term: Tension headache (excl migraine) System Organ Class: 100000004852

Interventions

Trade Name: pramipexole 1A FARMA Product Name: pramipexole 1 A Farma Pharmaceutical Form: Tablet Other descriptive name: PRAMIPEXOLE HYDROCHLORIDE HYDRATE Concentration unit: mg milligram(s) Concentra

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: whiplash associated disorder grade 2 tension type headache Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 20 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: age < 50 years no previous whiplash no other chronic pain condition no other chronic diseases pregnancy no safe contraception

Design outcomes

Primary

Measure	Time frame
Main Objective: to relieve neck pain and head ache;Secondary Objective: to improve coordination of head movements;Primary end point(s): relieve of neck pain and headache;Timepoint(s) of evaluation of this end point: prior to treatment 1. week pramipexole 0.18 mg 2. week pramipexole 0.36 mg 3. week pramipexole 0.54 mg A option: To continue treatment for 4 weeks B option: To discontinue treatment and check after 4 weeks	—

Measure

Time frame

Main Objective: to relieve neck pain and head ache;Secondary Objective: to improve coordination of head movements;Primary end point(s): relieve of neck pain and headache;Timepoint(s) of evaluation of this end point: prior to treatment 1. week pramipexole 0.18 mg 2. week pramipexole 0.36 mg 3. week pramipexole 0.54 mg A option: To continue treatment for 4 weeks B option: To discontinue treatment and check after 4 weeks

—

Secondary

Measure	Time frame
Secondary end point(s): improve coordination of head movements;Timepoint(s) of evaluation of this end point: prior to treatment 1. week pramipexole 0.18 mg 2. week pramipexole 0.36 mg 3. week pramipexole 0.54 mg A option: To continue treatment for 4 weeks B option: To discontinue treatment and check after 4 weeks	—

Countries

Denmark

Contacts

Public ContactDepartment of Neurology

Bispebjerg Hospital

astrup1943@gmail.com004540332725

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026